By Colin Kellaher
Travere Therapeutics shares rose sharply in early trading Tuesday after the biopharmaceutical company said it plans to seek expanded Food and Drug Administration approval of its kidney-disease drug Filspari in focal segmental glomerulosclerosis, or FSGS, around the end of March.
Shares of the San Diego company were recently up 9.8% at $23.16 in premarket trading.
Travere said the filing will be based on existing data results from its Phase 3 and Phase 2 interventional studies of Filspari in the rare kidney disorder, which is a leading cause of kidney failure.
The company said there are currently no FDA-approved treatments for FSGS, a condition in which the kidney's filtering units become scarred or hardened, leading to proteinuria (protein in the urine), kidney failure and other complications.
Travere said the results of its studies are in alignment with the recent findings of a group of experts that lowering proteinuria levels could be a better gauge of how well treatments for FSGS are working.
Filspari is currently approved to slow kidney-function decline in adults with the chronic kidney disease primary immunoglobulin A nephropathy who are at risk for disease progression.
Travere reported Filspari net product sales of nearly $82.6 million for the first nine months of 2024.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 11, 2025 08:43 ET (13:43 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。